Europe
The takeover is part of the French biotech giant’s “Play to Win” strategy of growing its global vaccines pipeline through the acquisition of promising projects and companies.
Pfizer veteran Phil Dormitzer will assume the role of Global Head of Vaccines beginning Friday.
Quell Therapeutics scooped up $156 million in a Series B round this week. The company utilizes regulatory T cells to treat a variety of autoimmune and inflammatory diseases.
The World Health Organization officially declared omicron – aka. B.1.1.529 – a variant of concern (VOC) on Friday.
Bonus BioGroup’s product is back in the news again as its cell therapy promises to treat late-stage COVID-19.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Vaccibody has changed its name to Nykode Therapeutics. “Nykode” means “new code,” which plays on the potential of the company to generate novel codes and innovative patient therapies.
After indicating it might entertain a sale, Novartis may receive an offer from investment group EQT and the Struengmann family for its generic unit Sandoz.
Switzerland-based Vifor Pharma is acquiring Spain’s Sanifit Therapeutics and another Swiss company, Inositec.
A Chinese professor at the University of Copenhagen in Denmark is under scrutiny over undisclosed ties to the Chinese military.
PRESS RELEASES